1H-Benzimidazole-5-carboxamide, 1,1'-(1,4-butanediyl)bis[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-

Product Name1H-Benzimidazole-5-carboxamide, 1,1'-(1,4-butanediyl)bis[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-
CAS2138300-40-8
MFC34H38N12O4
MW678.74
EINECS
MOL File2138300-40-8.mol

Chemical Properties

Density	1.48±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMSO: slightly soluble
form	A solid
pka	11.97±0.43(Predicted)
color	White to gray
InChIKey	ICZSAXDKFXTSGL-UHFFFAOYSA-N
SMILES	C(N1C(NC(C2N(CC)N=C(C)C=2)=O)=NC2=CC(C(N)=O)=CC=C21)CCCN1C(NC(C2N(CC)N=C(C)C=2)=O)=NC2=CC(C(N)=O)=CC=C21

Usage And Synthesis

Uses

STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function[1].

Biological Activity

STING agonist-4 is a stimulator of receptor agonists of the interferon gene (STING) with an apparent inhibition constant IC50 of 20 nM, It is a compound containing two symmetrically related aminobenzimidazoles (ABZI ) based compounds.

in vitro

STING agonist-4 (Compound 2) (0.3-30 μM; 2 hours) causes phosphorylation of IRF3 and STING that is inhibited by the TBK1 inhibitor BX795 and induces dose-dependent secretion of IFN-β with an EC ₅₀ of 3.1 μM. STING agonist-4 (Compound 2) (0.001 nM-1 μM) inhibits binding of full-length STING to the solid support with an apparent dissociation constant (K _{d < /sub> ) of approximately 1.6 nM. It (Compound 2) (0-100 μM) is 18-fold more potent than cGAMP (an endogenous STING ligand), with an EC ₅₀ of 53.9 μM. STING agonist-4 (Compound 2) (3 μM; 4 hours) promotes production of interferon γ-induced protein 10 (IP-10), IL-6 and TNF-α by a mechanism that is dependent on STING-mediated activation of TBK1.}

Cell Viability Assay

< td class="col1"> Result:

Cell Line:	Human peripheral blood mononucl ear cells (PBMCs)
Concentration:	0.3 μM, 1 μM, 3 μM, 10 μM and 30 μM
Incubation Time:	2 hours
Caused phosphorylation of IRF3 and STING and induced secretion of IFN-β.

target

IC50: 20 nM (STING agonist-4)

References

[1] Ramanjulu JM et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Dec;564(7736):439-443. DOI:10.1038/s41586-018-0705-y

1H-Benzimidazole-5-carboxamide, 1,1'-(1,4-butanediyl)bis[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]- Supplier

Related Product Information

Send Inquriy